Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REPLIGEN CORPRGEN · Entity 486 | Director | May 23, 2019 | June 19, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REPLIGEN CORP
Report date May 23, 2019 · Filed June 19, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,709 |
Last balance in matching sequence
After 2019-05-23 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2019-05-23 · Exercise / conversion · Acquired 24,000 · Balance 64,709 Row 2 · 2019-05-23 · Sale · Disposed 4,734 · Balance 59,975 F1: Sale of common stock to cover the exercise price and a portion of the tax liability resulting from the exercise of Mr. Cooper's stock options was allowed pursuant to an exception to a lock-up agreement, signed by Mr. Cooper on April 26, 2019 in connection with the public offering of the Company's common stock. F2: $66.91 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.42 to $67.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2019-05-23 · Sale · Disposed 266 · Balance 59,709 F1: Sale of common stock to cover the exercise price and a portion of the tax liability resulting from the exercise of Mr. Cooper's stock options was allowed pursuant to an exception to a lock-up agreement, signed by Mr. Cooper on April 26, 2019 in connection with the public offering of the Company's common stock. F3: $67.53 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.52 to $67.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2019-08-24 | Direct | 0 |
Reported balance
After 2019-05-23 transaction · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · 2019-05-23 · Exercise / conversion · Disposed 24,000 · Balance 0 F4: This option is currently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of common stock to cover the exercise price and a portion of the tax liability resulting from the exercise of Mr. Cooper's stock options was allowed pursuant to an exception to a lock-up agreement, signed by Mr. Cooper on April 26, 2019 in connection with the public offering of the Company's common stock.
F2: $66.91 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.42 to $67.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: $67.53 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.52 to $67.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: This option is currently exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2019 Filed May 28, 2019 20:17 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 266 | $67.53 | $17,962.98 |
DisclosureSEC source: 0000899243-19-014849 · doc4.xml · nonDerivative · entry 2 COOPER GLENN L MD · CIK 0001046351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,709 F1 · kind: Sale of common stock to cover the exercise price and a portion of the tax liability resulting from the exercise of Mr. Cooper's 24,000 stock options was allowed pursuant to an exception to a lock-up agreement, signed by Mr. Cooper on April 26, 2019 in connection with the public offering of the Company's common stock. F3 · price: $67.53 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.52 to $67.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 23, 2019 Filed May 28, 2019 20:17 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,734 | $66.91 | $316,751.94 |
DisclosureSEC source: 0000899243-19-014849 · doc4.xml · nonDerivative · entry 1 COOPER GLENN L MD · CIK 0001046351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,975 F1 · kind: Sale of common stock to cover the exercise price and a portion of the tax liability resulting from the exercise of Mr. Cooper's 24,000 stock options was allowed pursuant to an exception to a lock-up agreement, signed by Mr. Cooper on April 26, 2019 in connection with the public offering of the Company's common stock. F2 · price: $66.91 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.42 to $67.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 23, 2019 Filed Jun 19, 2019 23:04 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0000899243-19-017486 · doc4a.xml · derivative · entry 4 COOPER GLENN L MD · CIK 0001046351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2019-08-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| May 23, 2019 Filed Jun 19, 2019 23:04 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 266 | $67.53 | $17,962.98 |
DisclosureSEC source: 0000899243-19-017486 · doc4a.xml · nonDerivative · entry 3 COOPER GLENN L MD · CIK 0001046351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,709 F1 · kind: Sale of common stock to cover the exercise price and a portion of the tax liability resulting from the exercise of Mr. Cooper's stock options was allowed pursuant to an exception to a lock-up agreement, signed by Mr. Cooper on April 26, 2019 in connection with the public offering of the Company's common stock. F3 · price: $67.53 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.52 to $67.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 23, 2019 Filed Jun 19, 2019 23:04 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,734 | $66.91 | $316,751.94 |
DisclosureSEC source: 0000899243-19-017486 · doc4a.xml · nonDerivative · entry 2 COOPER GLENN L MD · CIK 0001046351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,975 F1 · kind: Sale of common stock to cover the exercise price and a portion of the tax liability resulting from the exercise of Mr. Cooper's stock options was allowed pursuant to an exception to a lock-up agreement, signed by Mr. Cooper on April 26, 2019 in connection with the public offering of the Company's common stock. F2 · price: $66.91 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.42 to $67.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 23, 2019 Filed Jun 19, 2019 23:04 UTC Amendment | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 24,000 | $5.00 | $120,000.00 |
DisclosureSEC source: 0000899243-19-017486 · doc4a.xml · nonDerivative · entry 1 COOPER GLENN L MD · CIK 0001046351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:10 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,109 | $0.00 Strike: $67.71 | $0.00 |
DisclosureSEC source: 0000899243-19-013992 · doc4.xml · derivative · entry 2 COOPER GLENN L MD · CIK 0001046351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,109 Underlying: Common Stock · 2,109 shares Expires 2029-05-15 F2 · derivative.exercise_date: Award vests in full one year from grant date on May 15, 2020. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:10 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 923 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-013992 · doc4.xml · nonDerivative · entry 1 COOPER GLENN L MD · CIK 0001046351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,709 F1 · shares: Mr. Cooper was awarded 923 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 15, 2020. The restricted stock units may be settled only be delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 16, 2018 Filed May 17, 2018 20:43 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 3,304 | $0.00 Strike: $42.07 | $0.00 |
DisclosureSEC source: 0001140361-18-024447 · doc1.xml · derivative · entry 2 COOPER GLENN L MD · CIK 0001046351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,304 Underlying: Common Stock · 3,304 shares Expires 2028-05-16 F2 · derivative.exercise_date: Award vests in full one year from grant date on May 16, 2019. Read SEC document |
| May 16, 2018 Filed May 17, 2018 20:43 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 1,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-024447 · doc1.xml · nonDerivative · entry 1 COOPER GLENN L MD · CIK 0001046351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,786 F1 · shares: Dr. Cooper was awarded 1,486 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The Restricted Stock Units vest on May 16, 2019. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:00 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,434 | $0.00 Strike: $38.76 | $0.00 |
DisclosureSEC source: 0001140361-17-021757 · doc1.xml · derivative · entry 2 COOPER GLENN L MD · CIK 0001046351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,434 Underlying: Common Stock · 2,434 shares Expires 2027-05-18 F2 · derivative.exercise_date: Award vests in full one year from grant date on May 18, 2018. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:00 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 1,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-021757 · doc1.xml · nonDerivative · entry 1 COOPER GLENN L MD · CIK 0001046351 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,300 F1 · shares: Dr. Cooper was awarded 1,206 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The Restricted Stock Units vest on May 18, 2018. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.